Navigation Links
Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
Date:9/28/2010

worldwide approvals, Tigris offers large pharmaceutical drug development expertise in conjunction with the agility and speed of a small organization.Contact:   For Tigris PharmaceuticalsTigris Pharmaceuticals, Inc.(239) 444-5400info@tigrispharma.comThis news release contains forward-looking statements.  Such statements are valid only as of today, and Tigris disclaims any obligation to update this information.  These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on current beliefs and expectations as to such future outcomes.  Drug development involves a high degree of risk.  Factors that might cause such a material difference include, among others uncertainties related to Tigris' ability to attract and retain partners for its technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, its pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates from other pharmaceutical companies, product pricing and third party reimbursement.


'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
3. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Research and Markets has announced the ... Film Industry Report 2014" report to their offering. ... Global And Chinese Medical X-Ray Film Industry Report 2014 ... state of the Global medical X-ray film industry with ... provides a basic overview of the industry including definitions, ...
(Date:7/11/2014)... Australia , July 11, 2014  Australian drug ... announced that it has raised A$19.3 million via a ... Europe , the U.S., Asia ... A$3 million from a share purchase plan (SPP) to ... million will be made in two tranches. ...
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... (PRWEB) July 12, 2014 The largest ... Centers, is pleased to announce that it will be ... This new facility will join four Atlanta-based Nova Medical ... located at 3209 Deans Bridge Road, and will be ... Friday. , “With Nova’s treatment philosophy of rapid ...
(Date:7/11/2014)... 12, 2014 Recently, DressyQuinceanera.com, a well-known ... Quinceanera Dama dresses to its online category. Furthermore, ... offered at deeply discounted rates, up to 62% off. ... are equally excellent in terms of quality and style. ... Similar discounts are also offered for the company’s other ...
(Date:7/11/2014)... Down reports that tickets to the Argentina vs. Germany ... between Brazil and Netherlands are in high demand. ... 12th at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal ... July 13th at Estadio Jornalista Mario Filho - Estadio do ... Cup are guaranteed to be authentic and are covered by ...
(Date:7/11/2014)... News) -- Reducing the number of deer in an ... and other tick-borne infections among people, new research indicates. ... manipulated to reduce human interactions with deer, infected nymphal ... researchers wrote. White-tailed deer are the primary host ... people. The study included nearly all the permanent ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Volunteers from ... against drug abuse this week with drug education lectures, ... education booklet distribution in cities around the world. , ... U.S. National Institute on Drug Abuse, abuse of alcohol ... annually in crime, lost work, decreased productivity and healthcare. ...
Breaking Medicine News(10 mins):Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3
... with effects of prescription drugs for heart troubles, researcher says ... of Americans who are taking traditional herbal medications for heart ... new report says. , "They may be safe," said Dr. ... Arizona, and author of a report in the Feb. 9 ...
... ... ability to convert into a stylish, comfortable footrest , ... Las Vegas (PRWEB) February 1, 2010 -- ... Chair® Recliners and other wellness solutions, announced today the introduction of its new and ...
... androgen deprivation, official says , MONDAY, Feb. 1 ... the physicians who treat them are being warned ... the malignancy might increase the risk of heart ... substantial amount of data demonstrating that ADT adversely ...
... scored lowest on test also had worst outcomes, study reports, ... or thinking abilities could signal an increased likelihood for a ... men who were not diagnosed as having dementia but who ... greatly increased risk for stroke. , It,s not yet clear ...
... , Less serious recurrence seen with Ponseti casting method , ... in a thousand babies born in the United States , but ... feet compatible with an active, normal lifestyle. A new study in the ... Joint Surgery (JBJS) compared two common treatment options for clubfoot – ...
... , GREENWOOD VILLAGE, Colo. , Feb. ... revenue cycle solutions for the healthcare industry, announced today ... electronic EDI 278 transaction to UnitedHealthcare conforming to new ... UnitedHealthcare requests hospitals to submit EDI notification of each ...
Cached Medicine News:Health News:Herbal Remedies Can Cause Cardiac Problems 2Health News:Herbal Remedies Can Cause Cardiac Problems 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 2Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 3Health News:Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves 4Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:Poor Mental Functioning May Predict Stroke 2Health News:Poor Mental Functioning May Predict Stroke 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 2Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 3Health News:Study Finds Ponseti Method of Clubfoot Correction Leads to Lower Surgical Rates and Less Revision Surgery 4Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 2Health News:Recondo Technology Announces Omni278 UnitedHealthcare Admission Notification Service 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: